Patents by Inventor Bruce Follows

Bruce Follows has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • PYRROLOTRIAZINONES AND IMIDAZOTRIAZINONES AS UBIQUITIN-SPECIFIC PROTEASE 7 INHIBITORS
    Publication number: 20160185786
    Abstract: The invention relates to inhibitors of USP7 inhibitors useful in the treatment of cancers, neurodegenerative diseases, immunological disorders, inflammatory disorders, cardiovascular diseases, ischemic diseases, viral infections and diseases, and bacterial infections and diseases, having the Formula: where R1, R2, R3, R4, R5, R5?, R6, X1, X2, m, and n are described herein.
    Type: Application
    Filed: December 29, 2015
    Publication date: June 30, 2016
    Inventors: Stephanos Ioannidis, Adam Charles Talbot, Bruce Follows, Alexandre Joseph Buckmelter, Minghua Wang, Ann-Marie Campbell
  • Inhibitors of protein tyrosine phosphatase 1B
    Publication number: 20050203087
    Abstract: Protein tyrosine phosphatases (PTPases) such as PTP1B can play a role in regulating a wide variety of cellular responses such as insulin signaling. Substituted thiophene compounds such as, for example, 2-carboxyl, 3-carboxymethoxy, 5-aryl substituted thiophenes, can inhibit PTP1B and thereby induce greater insulin sensitivity. Accordingly, PTP1B inhibition can provide an alternate treatment for PTPase-mediated disorders such as diabetes.
    Type: Application
    Filed: February 23, 2005
    Publication date: September 15, 2005
    Inventors: Jinbo Lee, Zhao-Kui Wan, Douglas Wilson, Bruce Follows, Steven Kirincich, Michael Smith, Jun-Jun Wu, Kenneth Foreman, David Erbe, Yan-Ling Zhang, Weixin Xu, Steve Tam
  • Inhibitors of protein tyrosine phosphatase 1B
    Publication number: 20050203081
    Abstract: Protein tyrosine phosphatases (PTPases) such as PTP1B can play a role in regulating a wide variety of cellular responses such as insulin signaling. Substituted bicyclic fused-thiophene compounds can inhibit PTP1B and thereby induce greater insulin sensitivity. Accordingly, PTP1B inhibition can provide an alternate treatment for PTPase-mediated disorders such as diabetes.
    Type: Application
    Filed: February 23, 2005
    Publication date: September 15, 2005
    Inventors: Jinbo Lee, Steve Kirincich, Michael Smith, Douglas Wilson, Bruce Follows, Zhao-Kui Wan, Diane Joseph-McCarthy, David Erbe, Yan-Ling Zhang, Weixin Xu, Steve Tam